Scriphessco

Scriphessco produces a range of medical devices primarily focused on pain management and therapeutic applications. These include single-use transcutaneous electrical stimulation electrodes, reusable hot/cold therapy packs for reducing pain and inflammation, skin topical coupling gels to improve conductivity during electrotherapy, and an ultrasound contrast medium designed for transuterine administration. Each device is tailored to enhance patient care in specific clinical scenarios.

Scriphessco is based in the United States. Since the company operates within the U.S., its devices are subject to FDA regulations, including classification under the agency’s risk-based system. The location also means its products are listed in the FDA’s Unique Device Identifier (UDI) database, ensuring traceability and compliance with U.S. regulatory requirements.

Scriphessco’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry is critical for tracking and verifying medical devices in the U.S. market, ensuring transparency and compliance with regulatory standards. Listing in the UDI database helps healthcare providers and regulators confirm the legitimacy and classification of the devices.

Scriphessco’s devices are classified under the FDA’s risk-based system as either Class I or Class II. Class I devices generally pose minimal risk and are subject to general controls, while Class II devices require additional performance standards to ensure safety and effectiveness. The classification depends on the device’s intended use and potential risk to patients, as outlined in the FDA’s regulatory framework.